Novel therapies for cutaneous T-cell lymphoma: what does the future hold?

Area of Science:

• Oncology
• Dermatology
• Hematology

Background:

• Cutaneous T-cell lymphomas (CTCLs) are extranodal non-Hodgkin lymphomas, with mycosis fungoides (MF) being the most common subtype.
• Current standard therapies for MF often stabilize the disease but rarely achieve a cure, highlighting the need for novel treatment strategies.

Purpose of the Study:

• This review discusses promising new therapeutic approaches for managing mycosis fungoides and other rare CTCLs.
• The aim is to provide an overview of innovative treatments and emerging targets in CTCL therapy.

Main Methods:

• The review synthesizes information on targeted therapies, including antibodies against malignant T-cell surface molecules (e.g., brentuximab).
• It covers novel chemotherapeutic agents (e.g., pralatrexate), small-molecule compounds (e.g., panobinostat), and emerging targets like anti-IL-31.
• Discussion includes immune checkpoint inhibitors (e.g., anti-PD1) for leukaemic CTCL variants and stem-cell transplantation.

Main Results:

• Significant advancements have been made in CTCL treatment with the development of innovative therapies.
• Targeted therapies, novel chemotherapeutics, and small-molecule compounds show promise in managing CTCLs.
• Immune checkpoint inhibitors and stem-cell transplantation are also being explored as potential treatment options.

Conclusions:

• New and promising therapies are advancing the treatment landscape for CTCLs.
• Despite progress, there remains an urgent need to identify and rigorously test additional therapeutic targets in well-designed clinical trials.